0000000000711044

AUTHOR

Michael Lehrke

showing 2 related works from this author

Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk

2021

Background Diabetes and hypertension are risk factors for renal and cardiovascular outcomes. Data on the association of achieved blood pressure (BP) with renal outcomes in patients with and without diabetes are sparse. We investigated the association of achieved SBP, DBP with renal outcomes and urinary albumin excretion (UAE) in people with vascular disease. Methods In this pooled analysis, we assessed renal outcome data from high-risk patients aged 55 years or older with a history of cardiovascular disease, 70% of whom had hypertension, randomized to The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial and to Telmisartan Randomized Assessment Study in ACE In…

Ramiprilmedicine.medical_specialtyPhysiologyRenal functionAngiotensin-Converting Enzyme InhibitorsBlood Pressure030204 cardiovascular system & hematologyBenzoates03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusDiabetes MellitusInternal MedicinemedicineHumans030212 general & internal medicineCreatininebusiness.industryHazard ratioMiddle Agedmedicine.diseasechemistryCardiovascular DiseasesHeart Disease Risk FactorsHypertensionAlbuminuriaMicroalbuminuriamedicine.symptomTelmisartanCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of Hypertension
researchProduct

Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions

2020

Objective: In patients with diabetes mellitus, increased platelet reactivity predicts cardiac events. Limited evidence suggests that DPP-4 (dipeptidyl peptidase 4) influences platelets via GLP-1 (glucagon-like peptide 1)-dependent effects. Because DPP-4 inhibitors are frequently used in diabetes mellitus to improve the GLP-1-regulated glucose metabolism, we characterized the role of DPP-4 inhibition and of native intact versus DPP-4-cleaved GLP-1 on flow-dependent thrombus formation in mouse and human blood. Approach and Results: An ex vivo whole blood microfluidics model was applied to approach in vivo thrombosis and study collagen-dependent platelet adhesion, activation, and thrombus for…

Blood Platelets0301 basic medicineendocrine systemmedicine.medical_specialtyPlatelet AggregationPLATELET ACTIVATIONLinagliptin030204 cardiovascular system & hematologyDPP4Glucagon-Like Peptide-1 Receptorlaw.invention03 medical and health sciences0302 clinical medicinedipeptidyl peptidase 4Fibrinolytic AgentslawInternal medicineDiabetes mellitusmedicineAnimalsHumansPlateletIn patientThrombusglucose610 Medicine & healthDipeptidyl peptidase-4Mice KnockoutDipeptidyl-Peptidase IV InhibitorsChemistryPharmacology. TherapySitagliptin Phosphatedigestive oral and skin physiologyThrombosismedicine.diseaseGlucagon-like peptide-1Peptide Fragmentsglucagon-like peptide 1Mice Inbred C57BLMICE030104 developmental biologyEndocrinologyPhysiological flowdiabetes mellitusplateletsSuppressorHuman medicineCardiology and Cardiovascular MedicineSignal Transduction
researchProduct